Caris Life Sciences, Inc. (CAI) Research

Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally. The company is dedicated to transforming medical care by innovating and bringing to market advanced solutions that leverage molecular data and sophisticated machine learning algorithms. Its extensive suite of molecular diagnostic offerings includes MI Profile, a specialized solution analyzing tissue samples, and Caris Assure, a blood-based test designed for cancer treatment applications. Furthermore, Caris provides research and development support to biopharmaceutical customers, encompassing laboratory delivery, strategic data insights, and dedicated research initiatives. Established in 2008, the company maintains its corporate headquarters in Irving, Texas.

Market snapshot

Symbol
CAI
Price
$18.47
Day change
+3.42%
Market cap
$5.2B
P/E ratio
153.58x
52-week range
14.19-42.5
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$28.60

Peer companies

  • Abivax S.A. (ABVX)
  • Corcept Therapeutics Incorporated (CORT)
  • Cytokinetics, Incorporated (CYTK)
  • Halozyme Therapeutics, Inc. (HALO)
  • Jazz Pharmaceuticals plc (JAZZ)
  • Madrigal Pharmaceuticals, Inc. (MDGL)
  • Moderna, Inc. (MRNA)
  • Merus N.V. (MRUS)

Recent insider activity

  • POSTE GEORGE — A-Award (1600 shares) on 2026-05-29
  • Knowles Jonathan Kenneth Charles — A-Award (1600 shares) on 2026-05-29
  • Denton John Russel — F-InKind (6047 shares) on 2026-05-15
  • Power Luke Thomas — F-InKind (9771 shares) on 2026-05-15
  • Spetzler David Baxley — F-InKind (13856 shares) on 2026-05-15

Open Caris Life Sciences, Inc. (CAI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.